Skip to main content

Table 3 Effect of each parameter on PFS according to baseline values and to the variation between T1 value (after 1 month of therapy) and T0 value (baseline value). This difference has been indicated as delta value (Δ)

From: Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma

Parameter Univariate Two-variable Multivariablea
Variable Timepoint Value p HR Lower HR Upper HR p HR Lower HR Upper HR p HR Lower HR Upper HR
Platelets Basal  + 10,000      0.419 1.007 0.900 1.025
Δ Ref ≤ 25,000      0.039 1.398 1.016 1.922 0.116 1.310 0.935 1.836
White blood cell count Basal  + 100      0.001 1.006 1.002 1.010 0.069 0.990 0.979 1.001
Δ Ref ≤ 1920       < 0.001 2.063 1.396 3.049
Neutrophils Basal  + 100       < 0.001 1.011 1.007 1.015 0.003 1.022 1.008 1.037
Δ Ref ≤ 310      0.020 1.429 1.058 1.930
Lymphocytes Basal  + 100      0.054 0.981 0.962 1.000
Δ Ref ≥ -300       < 0.001 1.910 1.356 2.692
NL ratio Basal  + 1       < 0.001 1.176 1.078 1.284
Δ Ref ≤ 0.86       < 0.001 1.975 1.411 2.764 0.004 1.709 1.183 2.468
PL ratio Basal  + 1      0.156 1.001 0.999 1.003
Δ Ref ≤ 22.85      0.001 1.693 1.240 2.311
Age Basal  + 1 0.210 1.007 0.996 1.019     
Sex Basal Ref F 0.601 0.923 0.682 1.248     
Number of metastatic sites Basal Ref ≥ 3 0.013 0.686 0.509 0.925     
LDH Basal Ref elevated 0.001 0.581 0.420 0.803      0.070 0.729 0.518 1.026
  1. Statistically significant values in bold
  2. At the Δ timepoint the variables have been dichotomized and the “value” represents the reference category
  3. HR (hazard ratio) values are expressed in terms of risk of progression
  4. aAfter stepwise selection